Promoting personalised treatment
The aim of the PoCCardio project is to develop a point-of-care (PoC) tool which uses biological markers and polymorphisms from finger prick blood to help identify, classify and monitor patients with cardiovascular disease who are at high risk of further events.
The Tool
The portable device allows point-of-care (PoC) measurements of both proteomic biomarkers and genetic risk variants to improve overall management of high-risk patients.
Laboratory validation of the tool and biological markers will be undertaken, followed by a multinational clinical trial which will include existing and approved pharmaceuticals.
Health equity
The tool provides fast results independent of access to high-end care facilities and thereby helps increase social inclusiveness and stimulate acceptance.
Validation trials
The developed point-of-care tool will be tested and validated in two trials, involving patients at a high risk of recurrent cardiovascular events
Trial 2: Multinational clinical trial involving 1800+ people with recent myocardial infarction
Afraa Razouk was awarded first prize at the Transfrontier Meeting on Sensors and Biosensors on 18 September 2026 for her poster presentation of a genomic platform for SNP detection for cardiovascular point-of-care diagnostics
The CING Bioinformatics Group presented PoCCardio and how it supports personalised medicine for heart patients through the use of AI
PoCCardio Project
Personalised Medicine by using an Advanced Point-of-Care Tool for Stratified Treatment in High Risk Cardiovascular Patients
